Radiographic Findings in Bisphosphonate-Treated Patients With Stage 0 Disease in the Absence of Bone Exposure

Hutchinson, Matthew; O’Ryan, Felice; Chavez, Vicente; Lathon, Phenius V.; Sánchez, Gabriela; Hatcher, David; Indresano, A. Thomas; Lo, Joan C.

doi:10.1016/j.joms.2010.05.003

Cited by 106 publications

(95 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[23][24][25][26][27][28][29][30] Finally, in 2014, an AAOMS special committee released a third position paper [31] changing the term from BRONJ to medicationrelated ONJ (MRONJ) in order to include cases linked to the treatment with denosumab and those arising after antiangiogenic drugs and targeted therapies; the document enlarged the definition of disease to include cases with 'bone that can be probed through an intraoral or extraoral fistula in the maxillofacial region that has persisted for longer than 8 weeks' and confirmed the existence of a 'stage 0 category' for patients with signs and symptoms without bone exposure. On the other hand, an international task force recently confirms the ASBMR 2007 definition without the AAOMS 2009 and 2014 amends.…”

Section: Definition Of Onjmentioning

confidence: 99%

Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology

Fusco

Santini

Armento

et al. 2016

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Introduction: Osteonecrosis of the jaw (ONJ) is a clinically important, potentially painful and debilitating condition, which can affect the quality of life of cancer patients. Since 2003, ONJ appeared as a Bisphosphonate(BP)-related class effect, and the term Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) was widespread. Areas Covered: Under discussion in this review is the fact that ONJ cases have been reported after treatment including antiangiogenic agents and other “targeted therapy”, with and without BPs. Consequently, the comprehensive term Medication-Related Osteonecrosis of the Jaw (MRONJ) has been introduced. The clinical aspects and the prognosis of ONJ associated with these new drugs are still less reported, but basing on their pharmacodynamics, they could be different from the well-known BRONJ. Accordingly, recommendations largely in use for BRONJ should be extended to these new forms, but critically applied and with respect to the individual risk assessment. Expert Opinion: There is a high risk of underdiagnoses for ONJ due to a lack of awareness, and too much restrictive or incomplete diagnostic criteria; at the same time, with regard to ONJ associated to the new non –antiresorptive agents, described here, we observe the strong need to improve the defining of any distinguished feature in their diagnosis, prevention and therapy

show abstract

Section: Definition Of Onjmentioning

confidence: 99%

Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology

Fusco

Santini

Armento

et al. 2016

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

show abstract

“…However, [ 18 F] fluoride PET/CT as a functional molecular imaging technique may allow detection of subtle foci of increased bone remodeling, considered precursors to clinically overt BONJ. 20 PET images were acquired 30 minutes after the injection of the tracer in this study; hence, the detected signal originated almost entirely from radioactive fluoride incorporated into bone tissue, and direct perfusion effects of the tracer could thereby be excluded. 21 Extent of BONJ detected in […”

mentioning

confidence: 99%

Bisphosphonate-Induced Osteonecrosis of the Jaw: Comparison of Disease Extent on Contrast-Enhanced MR Imaging, [¹⁸F] Fluoride PET/CT, and Conebeam CT imaging

Guggenberger

Fischer

Metzler

et al. 2012

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

show abstract

“…En etapas tempranas de esta patología, sólo se observa una leve osteoesclerosis y engrosamiento de la lámina dura (Hutchinson et al, 2010). Por tanto, el examen más frecuentemente solicitado es una radiografía panorámica en lugar de una imagen en 3D.…”

Section: Discussionunclassified

Sinusitis Maxilar por Osteonecrosis Asociada a Bisfosfonatos en Pacientes con Cáncer de Mama: serie de Casos

Figueroa

Saez

Alvarado

et al. 2015

Int. J. Odontostomat.

View full text Add to dashboard Cite

FIGUEROA, L.; SÁEZ, F.; ALVARADO, B.; GALLARDO, P. & CIFUENTES, J.Sinusitis maxilar por osteonecrosis asociada a bisfosfonatos en pacientes con cáncer de mama: Serie de casos. Int. J. Odontostomat., 9(3):449-455, 2015. RESUMEN:Los bisfosfonatos (BF) son fármacos ampliamente utilizados como estabilizadores óseos en el tratamiento de metástasis óseas, osteoporosis, enfermedad de Paget, entre otras patologías, debido a sus efectos anti-tumorales y a la característica de inhibir la actividad osteoclástica. La osteonecrosis maxilar asociada a BF, hoy en día osteonecrosis maxilar asociada a fármacos (ONMF) es definida como la presencia de hueso expuesto, no-vascularizado y necrótico en la cavidad oral por un periodo mayor a ocho semanas, con una historia positiva de tratamiento con fármacos anti-reabsorción ósea (BP, inhibidores del ligando RANKL) y/o anti-angiogénicos y sin antecedentes de tratamiento con radiación o metás-tasis obvia en los maxilares. La frecuencia de ONMF es incierta. La mandíbula es más frecuentemente afectada por ONMF que el maxilar. Pocos casos de ONMF en el maxilar han sido descritos con un diagnostico de sinusitis maxilar simultáneo. Tres casos con sinusitis maxilar asociada a ONMF son presentados en este trabajo. Todos los pacientes fueron mujeres con una historia positiva de cáncer de mama y tratamiento con bisfosfonatos. Los primeros dos casos, desarrollaron ONMF después de una extracción del tercer molar maxilar. El tercer caso con ONMF en el maxilar, sólo tenía antecedentes de curetaje periodontal. Una tomografía computada fue realizada y mostró compromiso del seno maxilar en todos los pacientes. Modalidades diagnósticas para evaluar la extensión de la necrosis y el compromiso del seno, como también alternativas de tratamiento son descritas en este estudio. Finalmente, una revisión actualizada de la literatura es presentada.PALABRAS CLAVE: bisfosfonatos, osteonecrosis maxilar asociada a fármacos, sinusitis.

show abstract

Radiographic Findings in Bisphosphonate-Treated Patients With Stage 0 Disease in the Absence of Bone Exposure

Cited by 106 publications

References 37 publications

Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology

Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology

Bisphosphonate-Induced Osteonecrosis of the Jaw: Comparison of Disease Extent on Contrast-Enhanced MR Imaging, [¹⁸F] Fluoride PET/CT, and Conebeam CT imaging

Sinusitis Maxilar por Osteonecrosis Asociada a Bisfosfonatos en Pacientes con Cáncer de Mama: serie de Casos

Contact Info

Product

Resources

About

Radiographic Findings in Bisphosphonate-Treated Patients With Stage 0 Disease in the Absence of Bone Exposure

Cited by 106 publications

References 37 publications

Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology

Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology

Bisphosphonate-Induced Osteonecrosis of the Jaw: Comparison of Disease Extent on Contrast-Enhanced MR Imaging, [18F] Fluoride PET/CT, and Conebeam CT imaging

Sinusitis Maxilar por Osteonecrosis Asociada a Bisfosfonatos en Pacientes con Cáncer de Mama: serie de Casos

Contact Info

Product

Resources

About

Bisphosphonate-Induced Osteonecrosis of the Jaw: Comparison of Disease Extent on Contrast-Enhanced MR Imaging, [¹⁸F] Fluoride PET/CT, and Conebeam CT imaging